In vivo, neutralization of CD73 activity promoted anti- tumor efficacy of the engineered NK cells against CD73+ human lung cancer xenografts, including a greater delay in tumor growth, no obvious toxicity, and increased tumor-infiltrating NK cells (Figure 1C-G). The gene discussed is NT5E; the disease is neoplasm.